Table 1. Patient characteristics according to presence or absence of neuropathic pain.
| Patients with neuropathic pain (*) N = 22 | Patients without neuropathic pain (**) N = 79 | TOTAL (***) N = 101 | ||
| Sex | Male | 14 (63.6%) | 59 (74.7%) | 73 (72.3%) |
| Female | 8 (36.4%) | 20 (25.3%) | 28 (27.7%) | |
| Mean age | 39.91 years | 39.19 years | 39.34 years | |
| WHO classification | MB | 20 (90.9%) | 74 (93.7%) | 94 (93.1%) |
| PB | 2 (9.2%) | 5 (6.3%) | 7 (6.9%) | |
| Leprosy reaction present | 15 (68.2%) | 51 (64.6%) | 66 (65.4%) | |
| Type of reaction | Type 1 reaction | 7 (31.8%) | 17 (21.6%) | 24 (23.8%) |
| ENL | 7 (31.8%) | 28 (35.4%) | 35 (34.7%) | |
| Neuritis | 1 (4.5%) | 2 (2.5%) | 3 (3.0%) | |
| Silent neuritis | 0 | 4 (5.1%) | 4 (4.0%) | |
| No reaction | 7 (31.8%) | 28 (35.4%) | 34 (33.7%) | |
| Other treatments | Prednisolone | 18 (81.8%) | 48 (60.8%) | 66 (65.4%) |
| Thalidomide | 3 (13.6%) | 23 (29.1%) | 26 (25.7%) | |
| Chloroquine | 3 (13.6%) | 16 (20.3%) | 19 (18.8%) | |
| Azathioprine | 1 (4.5%) | 9 (11.4%) | 10 (9.9%) | |
| Presence of patches | 16 (72.7%) | 53 (67.1%) | 69 (68.3%) | |
| Painful patches | 9 (40.9%) | 15 (19.0%) | 24 (23.8%) | |
| Thickened nerves | 15 (68.2%) | 31 (39.2%) | 46 (45.5%) | |
| Tender nerves | 10 (45.5%) | 9 (11.4%) | 19 (18.8%) | |
| Sensory impairment | 21 (95.5%) | 60 (76.0%) | 81 (80.2%) | |
| Motor impairment | 11 (50.0%) | 35 (44.3%) | 46 (45.5%) | |
| DN4 score | <4 / 10 | 0 | 73 (92.4%) | 73 (72.3%) |
| ≥4 / 10 | 22 (100.0%) | 6 (7.6%) | 28 (27.7%) | |
| Psychological morbidity | 9 (40.9%) | 6 (7.6%) | 15 (14.9%) | |
| Disability (WHO score of 1 or 2) | 11 (50.0%) | 33 (41.8%) | 44 (43.6%) |
*% of total patients with neuropathic pain (22);
**% of total patients without neuropathic pain (79);
***% of total sample population (101).